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Clinical immunity to Plasmodium falciparum malaria takes years to develop and is never complete.
One explanation for these observations is that antigenic variation enables malaria parasites to evade
humoral immunity; another is thatP. falciparum induces immune dysregulation, which inhibits the de-
velopment of protective cellular immunity. Research described by D’Ombrain et al. in this Cell Host &
Microbe issue probes how the parasite’s main virulence factor PfEMP-1 might significantly alter
human innate immune responses.Plasmodium falciparum erythrocyte
membrane protein-1 (PfEMP-1) is
a clonally variant, multidomain ligand
expressed on the surface of parasite-
infected red blood cells (iRBC). Most
PfEMP-1 variants mediate the adher-
ence of iRBC to CD36 receptors ex-
pressed on microvascular endothelial
cells. By this process, iRBC avoid
clearance from the blood stream by
the spleen and multiply to sufficiently
high numbers to cause symptomatic
disease. While iRBC adherence to mi-
crovessels is pathogenic, the expres-
sion of CD36 on macrophages and
dendritic cells (DC) suggests that
PfEMP-1 might also exert immunoreg-
ulatory and/or immunopathogenic ef-
fects. Recent in vitro studies have
shown that macrophages can ingest
nonopsonized iRBC in a PfEMP-1-
and CD36-dependent manner, which
may be important in the phagocytic
clearance of iRBC from nonimmune
hosts (McGilvray et al., 2000). Another
study suggested roles for PfEMP-1
and CD36 in the parasite’s inhibition
of DC function (Urban et al., 1999).
However, results obtained recently
from transgenic parasites that lack
PfEMP-1 and parasites that express
a non-CD36-binding PfEMP-1 variant
indicate that neither PfEMP-1 nor
CD36 are involved in iRBC-DC interac-
tions (Elliott et al., 2007).
D’Ombrain et al. have now used
transgenic parasites to explore an-
other potential immunoregulatory
function of PfEMP-1, as described in
this issue of Cell Host & Microbe
(D’Ombrain et al., 2007b). These andother investigators previously reported
that iRBC activate malaria-naive pe-
ripheral blood mononuclear cells
(PBMC), as indicated by the rapid pro-
duction (within 24 hr) of IFN-g from
gd-T cells, NK cells, and naive ab-T
cells (D’Ombrain et al., 2007a). Con-
ceivably, the innate production of
IFN-g could help to reduce parasite
replication by activating macrophages
to ingest parasites in the spleen. To
determine whether PfEMP-1 might
specifically modulate this IFN-g re-
sponse, these investigators used
a pair of isogenic P. falciparum lines
that differ only in the presence or ab-
sence of PfEMP-1. They found that
iRBC lacking PfEMP-1 induce much
higher levels of IFN-g than iRBC ex-
pressing PfEMP-1, suggesting that
PfEMP-1 suppresses the innate IFN-g
response to iRBC. Most of the IFN-g
was produced by gd-T cells, with NK
cells and naive ab-T cells producing
small amounts of this cytokine. Similar
results were obtained with a parasite
line that expresses a PfEMP-1 variant
which does not bind CD36. Thus, it
seems that PfEMP-1 suppresses
IFN-g production from malaria-naive
PBMC by a mechanism that does not
involve CD36-expressing macro-
phages or DC.
Based on these and other data,
D’Ombrain et al. are now able to pro-
pose a more detailed model of innate
immunity to malaria (Figure 1). When
iRBC rupture as part of their life cycle,
parasite products (e.g., GPI and he-
mozoin) bind to Toll-like receptors
and other pattern recognition recep-Cell Host & Microbetors on macrophages and DC. These
antigen-presenting cells display addi-
tional parasite antigens to various im-
mune effector cells. One example is
the presentation of phosphoantigens
by plasmacytoid DC to gd-T cells.
The rapid IFN-g responses by gd-T
cells, NK cells, and naive ab-T cells
are each suppressed by PfEMP-1.
Since CD36-expressing macrophages
and DC are not involved in this sup-
pression, the authors propose that
PfEMP-1 might exert its suppressive
effects through a common receptor
on NK and T cells, such as an inhibitory
NK receptor or another constitutive
negative regulator of leukocyte activa-
tion (Figure 1, bottom panel).
If this model operates in vivo, two
interpretations can be made. If the
early IFN-g response activates macro-
phages to clear parasites by phagocy-
tosis, then the suppression of this
cytokine surge by PfEMP-1 might im-
prove parasite survival—an outcome
presumably detrimental to the host.
On the other hand, reduced levels of
IFN-gmight ameliorate disease sever-
ity, as high levels of this cytokine have
been associated with disease severity
in animal models and human malaria
studies (Hunt and Grau, 2003). One
might then hypothesize that PfEMP-1
reduces IFN-g levels just enough to al-
low parasites to survive in reasonable
numbers and also reduce the chance
of causing severe, life-threatening dis-
ease in the host. Like IFN-g, TNF and
other cytokines have been plausibly
implicated as having both antiparasitic
and immunopathogenic effects during2, August 2007 ª2007 Elsevier Inc. 75
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den, 2003). Some innate immune re-
sponses thus seem to work as a two-
edged sword in producing cytokine
levels that are pathogenic and protec-
tive in vivo.
Further work to clarify PfEMP-1-
mediated effects on immune cells
and their relevance to antimalarial im-
munity in vivo are clearly needed. In
some of their experiments, D’Ombrain
et al. used a parasite line containing
populations of parasites expressing
multiple CD36-binding variants of
PfEMP-1 (D’Ombrain et al., 2007b).
Whether clonal variants of PfEMP-1
expressed by naturally circulating par-
asites vary in their ability to suppress
IFN-g is not yet determined. Since
PfEMP-1 variants differ in their affinity
for CD36, it is conceivable that
PfEMP-1 variants might also differ in
their affinity for putative receptors on
T and NK cells. Also, PfEMP-1 variants
that bind ICAM-1 (the receptor for76 Cell Host & Microbe 2, August 2007 ª2iRBC in cerebral microvessels) could
perform very differently in PBMC stim-
ulation assays, as most leukocytes ex-
press ICAM-1. The possibility that host
genetic polymorphisms might influ-
ence the development of innate immu-
nity can now be considered a promis-
ing area of research. Recent data
have shown that hemoglobin C, a he-
moglobin variant associated with ma-
laria protection in West Africa, mark-
edly reduces the amount of PfEMP-1
on the iRBC surface (Fairhurst et al.,
2005). It is possible that some natu-
rally-selected variants of hemoglobin
and erythrocytes lessen PfEMP-1-
mediated suppression of IFN-g,
thereby interfering with the ability of
the parasite to control host defense
mechanisms against infection.
Determining whether PfEMP-1-
mediated suppression of IFN-g might
influence parasite survival and dis-
ease-controlling immunity in malaria-
experienced individuals will not be007 Elsevier Inc.easy. In Papua New Guinea, where
Schofield and colleagues are conduct-
ing a longitudinal cohort study, it is
likely that naturally-circulating para-
sites expressmyriad PfEMP-1 variants
and that study participants will have
varying titers and repertoires of
anti-PfEMP-1 antibodies. These anti-
bodies could interfere with the iRBC-
leukocyte interactions that promote
IFN-g suppression. Human popula-
tions of Papua New Guinea also carry
extremely high frequencies of RBC-re-
lated polymorphisms known to influ-
ence disease severity, such as those
associated with ovalocytosis and al-
pha-thalassemia (Allen et al., 1997;
Genton et al., 1995). Accounting for
various confounders of PfEMP-1-
mediated events while maintaining
a focus on activated gd-T cells and
IFN-g will be an immense challenge,
but one well worth the effort.
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D.J. (1999). Nature 400, 73–77.Figure 1. A Model of Innate Immunity to P. falciparum Malaria
Top panel: Hemozoin and GPI from iRBC activate macrophages and both myeloid and plasmacy-
toid DC. These antigen-presenting cells display additional parasite antigens to naive-T and NK
cells. By this process, transgenic iRBC that lack PfEMP-1 stimulate the production of large
amounts of IFN-g mostly from gd-T cells. iRBC that express PfEMP-1 induce lower levels of
IFN-g from naive-T and NK cells in a CD36-independent manner, indicating that macrophages
and DC are not involved in IFN-g suppression. Instead, the authors propose that PfEMP-1 sup-
presses IFN-g production directly by binding to a putative receptor that is common to naive
ab-T, NK, and gd-T cells (bottom panel).
